| Literature DB >> 16713481 |
Abstract
This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16713481 DOI: 10.1016/j.jaad.2005.08.032
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 11.527